Role of NLRP3 Inflammasomes in Neurodegenerative Diseases.

Nagihan Demirtaş, Büşra Şahin Mazlumoğlu, Şaziye Sezin Palabıyık Yücelik
Author Information
  1. Nagihan Demirtaş: Department of Pharmaceutical Toxicology, Atatürk University Faculty of Pharmacy, Erzurum, Turkey.
  2. Büşra Şahin Mazlumoğlu: Department of Pharmaceutical Toxicology, Atatürk University Faculty of Pharmacy, Erzurum, Turkey.
  3. Şaziye Sezin Palabıyık Yücelik: Department of Pharmaceutical Toxicology, Atatürk University Faculty of Pharmacy, Erzurum, Turkey.

Abstract

Large-scale neuronal degeneration in the human brain is a hallmark of neurodegenerative diseases. These diseases range in location and cause, but they all have neurodegenerative characteristics in common. Neurodegenerative diseases, which have almost no efective treatment options, tend to progress irreversibly and cause large socioeconomic and healthcare costs. In recent years, due to the increase in the elderly population, neurodegenerative diseases that have a risk factor with aging are becoming increasingly common. Evidence that neurodegenerative diseases, which have an important place in public health, may be caused by neuroinflammation, has led to comprehensive investigation of neurodegenerative diseases in this regard. Inflammasomes are innate immune system-associated multiproteins that regulate caspase-1 activation and induce inflammation. The NLRP3 inflammasome is the most researched inflammasome and also located in microglia, its activation mediates the maturation and secretion of the inflammatory cytokines interleukin1beta (IL-1β) and IL-18, thus exerting its efects in the central nervous system. Within the scope of this review, experimental and human studies evaluating the role of NLRP3 inflammasome activation and the efects of its inhibition in neurodegenerative diseases frequently encountered in society have been compiled with studies from past to present.

References

  1. Gene. 2023 Jul 30;875:147502 [PMID: 37224935]
  2. Mol Cell Endocrinol. 2022 Feb 15;542:111529 [PMID: 34906628]
  3. Glia. 2020 Feb;68(2):407-421 [PMID: 31596526]
  4. Trends Neurosci. 2022 Oct;45(10):733-748 [PMID: 36075783]
  5. Mol Neurodegener. 2016 Apr 16;11:28 [PMID: 27084336]
  6. Pharm Biol. 2023 Dec;61(1):1175-1185 [PMID: 37559448]
  7. Brain Pathol. 2017 Mar;27(2):213-219 [PMID: 27997058]
  8. Neurotoxicology. 2022 Mar;89:127-139 [PMID: 35121005]
  9. Front Pharmacol. 2022 Feb 16;13:845185 [PMID: 35250595]
  10. Genes (Basel). 2020 Jan 27;11(2): [PMID: 32012695]
  11. J Neuroimmunol. 2012 Feb 29;243(1-2):56-60 [PMID: 22230485]
  12. Neurobiol Aging. 2000 May-Jun;21(3):383-421 [PMID: 10858586]
  13. Mol Neurobiol. 2016 Dec;53(10):6709-6715 [PMID: 26659872]
  14. Brain Behav Immun. 2009 Aug;23(6):817-22 [PMID: 19275930]
  15. Gene. 2016 Feb 15;577(2):109-18 [PMID: 26657039]
  16. J Nanobiotechnology. 2022 Jul 14;20(1):322 [PMID: 35836190]
  17. Acta Neuropathol. 2022 Sep;144(3):393-411 [PMID: 35867112]
  18. Lancet Neurol. 2023 Jan;22(1):78-88 [PMID: 36410373]
  19. Biomed Pharmacother. 2023 Dec;168:115735 [PMID: 37852103]
  20. Int J Mol Sci. 2022 Aug 11;23(16): [PMID: 36012243]
  21. Neurochem Res. 2017 Apr;42(4):1104-1115 [PMID: 28247334]
  22. Psychiatry Clin Psychopharmacol. 2023 Jun 01;33(2):147-155 [PMID: 38765928]
  23. Curr Neuropharmacol. 2020;18(11):1106-1125 [PMID: 32484110]
  24. Neuron. 2018 Feb 21;97(4):742-768 [PMID: 29470968]
  25. Mol Aspects Med. 2021 Apr;78:100871 [PMID: 32703610]
  26. Inflammation. 2018 Feb;41(1):93-103 [PMID: 28936769]
  27. Cell. 2010 Mar 19;140(6):805-20 [PMID: 20303872]
  28. J Neuroinflammation. 2022 Dec 28;19(1):315 [PMID: 36577999]
  29. Curr Drug Deliv. 2022;19(8):860-873 [PMID: 34963433]
  30. Clin Exp Pharmacol Physiol. 2021 Aug;48(8):1103-1110 [PMID: 33686709]
  31. Glia. 2018 Aug;66(8):1736-1751 [PMID: 29665074]
  32. Annu Rev Pathol. 2011;6:193-222 [PMID: 21034221]
  33. Ageing Res Rev. 2014 May;15:6-15 [PMID: 24561250]
  34. JCI Insight. 2023 Feb 8;8(3): [PMID: 36602874]
  35. Aging Cell. 2022 May;21(5):e13623 [PMID: 35474599]
  36. Mov Disord. 2016 Mar;31(3):366-76 [PMID: 26853432]
  37. Nature. 2013 Jan 31;493(7434):674-8 [PMID: 23254930]
  38. Neurol Res. 2021 Sep;43(9):778-783 [PMID: 34130607]
  39. Neurotoxicology. 2022 May;90:197-204 [PMID: 35413380]
  40. Lung. 2022 Oct;200(5):561-572 [PMID: 36040529]
  41. J Immunol. 2010 Jul 15;185(2):974-81 [PMID: 20574004]
  42. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13046-50 [PMID: 20616033]
  43. Front Aging Neurosci. 2022 Jan 21;13:809433 [PMID: 35126093]
  44. Mol Neurodegener. 2016 Mar 03;11:23 [PMID: 26939933]
  45. J Neuroimmunol. 2014 May 15;270(1-2):56-60 [PMID: 24657029]
  46. Acta Neuropathol. 2011 Dec;122(6):657-71 [PMID: 22105541]
  47. Nat Immunol. 2008 Aug;9(8):857-65 [PMID: 18604209]
  48. Drug Discov Today. 2020 Jul;25(7):1146-1159 [PMID: 32442631]
  49. Cell Death Dis. 2017 Jun 29;8(6):e2905 [PMID: 28661482]
  50. BMC Geriatr. 2005 Jan 12;5:2 [PMID: 15647106]
  51. Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E6065-E6074 [PMID: 29895691]
  52. Glia. 2015 Dec;63(12):2260-73 [PMID: 26200799]
  53. Front Mol Neurosci. 2022 May 25;15:894298 [PMID: 35694441]
  54. EMBO Mol Med. 2019 Jun;11(6): [PMID: 31015277]
  55. Biochem Pharmacol. 2023 Mar;209:115435 [PMID: 36720356]
  56. Mol Neurobiol. 2018 Mar;55(3):2350-2361 [PMID: 28357805]
  57. Neuroimmunomodulation. 2017;24(1):29-39 [PMID: 28618410]
  58. Mol Neurobiol. 2024 Mar;61(3):1318-1330 [PMID: 37702910]
  59. J Mol Neurosci. 2022 Nov;72(11):2292-2302 [PMID: 36333611]
  60. Cell. 2015 Jan 15;160(1-2):62-73 [PMID: 25594175]
  61. Inflammopharmacology. 2022 Dec;30(6):2197-2209 [PMID: 35948811]
  62. Clin Exp Immunol. 2022 May 12;207(3):378-386 [PMID: 35553640]
  63. Nat Med. 2021 Sep;27(9):1592-1599 [PMID: 34446931]
  64. Int J Neurosci. 2024 Jul;134(7):725-734 [PMID: 36525373]
  65. Neurosci Lett. 2020 Sep 25;736:135279 [PMID: 32726591]
  66. Int J Neurosci. 2004 Jan;114(1):75-81 [PMID: 14660069]
  67. Neuron. 2006 Feb 16;49(4):489-502 [PMID: 16476660]
  68. Chem Sci. 2022 Feb 21;13(10):2971-2980 [PMID: 35382471]
  69. J Neuroinflammation. 2005 Jun 20;2:15 [PMID: 15967035]
  70. Cell Death Differ. 2022 Mar;29(3):657-669 [PMID: 34625662]
  71. Mult Scler Relat Disord. 2020 Aug;43:102179 [PMID: 32470859]
  72. J Neurochem. 2022 Oct;163(2):94-112 [PMID: 35633501]
  73. Ageing Res Rev. 2021 Jan;65:101202 [PMID: 33161129]
  74. Biochem J. 2015 Nov 1;471(3):323-33 [PMID: 26272943]
  75. Nat Rev Neurol. 2021 Mar;17(3):157-172 [PMID: 33318676]
  76. Adv Med Sci. 2023 Sep;68(2):322-331 [PMID: 37716182]
  77. Neuroscience. 2014 Jun 6;269:184-91 [PMID: 24704432]
  78. J Neuroinflammation. 2023 Feb 2;20(1):21 [PMID: 36732771]
  79. J Neuroinflammation. 2023 Nov 22;20(1):274 [PMID: 37990334]
  80. Inflammation. 2024 Feb;47(1):404-420 [PMID: 37930487]
  81. Brain Behav Immun. 2021 Jan;91:771-783 [PMID: 33157255]
  82. J Neuroimmunol. 2020 Nov 12;350:577432 [PMID: 33220655]
  83. Annu Rev Neurosci. 2016 Jul 8;39:57-79 [PMID: 27050320]
  84. Nat Rev Neurosci. 2018 Oct;19(10):610-621 [PMID: 30206330]
  85. Toxicol Sci. 2017 Sep 1;159(1):64-75 [PMID: 28903492]
  86. Immunology. 2018 Jun;154(2):204-219 [PMID: 29513402]
  87. Sci Rep. 2023 Oct 19;13(1):17841 [PMID: 37857668]
  88. PLoS One. 2013 Jun 20;8(6):e66657 [PMID: 23885286]
  89. Int Immunopharmacol. 2019 Feb;67:458-464 [PMID: 30594776]
  90. Cytokine. 2019 Jul;119:113-118 [PMID: 30903865]
  91. Int J Biol Macromol. 2021 Nov 1;190:911-918 [PMID: 34492249]
  92. Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10480-5 [PMID: 22699511]
  93. NPJ Parkinsons Dis. 2018 Aug 15;4:24 [PMID: 30131971]
  94. Sci Transl Med. 2018 Oct 31;10(465): [PMID: 30381407]
  95. J Neuroinflammation. 2005 Jun 03;2:14 [PMID: 15935098]

Word Cloud

Created with Highcharts 10.0.0diseasesneurodegenerativeactivationNLRP3inflammasomehumancausecommonNeurodegenerativeInflammasomesefectsstudiesLarge-scaleneuronaldegenerationbrainhallmarkrangelocationcharacteristicsalmostefectivetreatmentoptionstendprogressirreversiblylargesocioeconomichealthcarecostsrecentyearsdueincreaseelderlypopulationriskfactoragingbecomingincreasinglyEvidenceimportantplacepublichealthmaycausedneuroinflammationledcomprehensiveinvestigationregardinnateimmunesystem-associatedmultiproteinsregulatecaspase-1induceinflammationresearchedalsolocatedmicrogliamediatesmaturationsecretioninflammatorycytokinesinterleukin1betaIL-1βIL-18thusexertingcentralnervoussystemWithinscopereviewexperimentalevaluatingroleinhibitionfrequentlyencounteredsocietycompiledpastpresentRoleDiseases

Similar Articles

Cited By